Pantherics Inc., a Milwaukee startup that is developing an innovative anti-inflammatory drug, recently received about $255,000 from the National Institutes of Health (NIH).
The funding will help the company “validate an optimal oral formulation” for its PI301 drug, which could be used to control asthma and other inflammatory conditions without traditional inhalers, according to a press release. That step is necessary before moving into human clinical testing.
PI301 was discovered by researchers at University of Wisconsin-Milwaukee’s Milwaukee Institute for Drug Discovery and Columbia University in New York, the release said. Pantherics was launched to commercialize novel drugs invented at UWM and was registered as an official company in 2017.